NeuroMab™ Anti-TDP43 Antibody(NRP-0422-P703)

Figure 1 depicts that TDP-0 antibody specifically recognizes TDP-43 oligomers.

1 ml SEC fractions were collected and dot blotted with TDP-0 (upper blot) and N-26o antibodies (lower blot).

Figure 2 depicts the presence of TDP-43 oligomers in FTLD-TDP patients.

In contrast to monomeric TDP-43 antibody, TDP-0 antibody does not stain nuclei, indicating specificity for misfolded TDP-43. The scale bar in all figures is 20 μm.

Figure 3 depicts that TDP-0 mAb exhibits higher specificity for TDP-43 oligomers.

Different concentrations of TDP-0 mAbs (1 -2 x 10"^g/mL) produced by TDP-O-3, -5, -8, -9 and -10 hybridoma cells were used in ELISA assay to detect SDS Denatured or undenatured TDP-43.

Figure 4 depicts that TDP-0 mAb exhibits higher specificity for purified TDP-43 oligomers.

Conditioned media of TDP-O-3, -5, -8, -9, and -10 hybridoma cell lines were used to detect TDP-43 oligomers and monomers by ELISA assay.

Figure 5 depicts TDP-0 monoclonal antibody rescue of TDP-43 oligomer-induced cytotoxicity.

MTT assay was performed to examine the cell viability of BE(2)-C cells. Data are presented as mean ± standard deviation. Statistical analysis was performed by one-way ANOVA, *p<0.05, **p<0.01, ***p<0.001. The results showed that TDP-43 oligomer-induced toxicity was significantly alleviated by TDP-0 antibody treatment.

Figure 6 depicts that TDP-43 oligomers are present and increase with age in a transgenic mouse model of FTLD-TDP.

Immunofluorescent staining of human TDP-43 and TDP-43 oligomers in brain sections of wild-type and 6- and 12-month-old TDP-43 Tg+/+ transgenic mice. Cells with anti-TDP oligomer staining, TDP-43 staining, and DAPI staining are shown (scale bar, 100 μm). Closed regions are presented at higher magnification in the last column (scale bar, 25 μm).